cvot tirzepatide In patients with type 2 diabetes and atherosclerotic cardiovascular disease, was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT trial results: https://nej.md/4qd5rLx Tirzepatide Matches Dulaglutide on Major

Weve had to develop payment plans specifically for people transitioning off medications like Cymbalta because their symptoms worsen before improving. Cymbalta Withdrawal: Why Patients Struggle to Stop Discontinuation syndrome is a common issue for people who want to stop taking Cymbalta

Vasoactive Intestinal Peptide (VIP), another gut-derived peptide, acts as a potent vasodilator and has positive inotropic effects on the heart

Patients should contact their healthcare provider if they experience severe or progressive hair loss that continues beyond 6 to 9 months, involves large bald patches, or significantly impacts quality of life and psychological well-being

Indication data were not available

Biomed Pharmacother 57:145155

Casciari J, Riordan H et al